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This masters’ thesis aims to examine the impact of the legalization of marijuana for recreational 
use on the death toll from opioid misuse in the state of Colorado. This investigation was done using the 
Synthetic Controls Method via data collected primarily from the CDC and IPUMS databases. The results 
indicate that the 2012 legalization policy in Colorado appears to reduce the number of deaths due to opioid 
overdoses.  
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One of the many issues at the forefront of the United States’ political landscape presently 
is the debate over the legalization of marijuana. Cannabis was classified as a Schedule I drug in 
the United States under the Controlled Substances Act of 1970 because it was considered to have 
no accepted medical use. In 2009 however, the American Medical Association (AMA) adopted a 
stance urging the federal government to review the case for rescheduling marijuana, stating that 
doing so would “facilitate research and development of cannabinoid-based medicine” (AMA, 
2009). Oregon was the first state in the country to decriminalize marijuana in 1973; but it wasn't 
until 1996 that legalization policies were enacted. Between the years 2000 to 2011, twelve states 
voted for the legalization of medical marijuana. However, as federal laws still classified marijuana 
as illegal, individuals could be indicted for consuming and possessing the drug. In 2012, Colorado 
became the first state to legalize recreational marijuana through Amendment 64. Washington state 
closely followed it, and since then, eight states as well as the District of Colombia have legalized 
it for recreational use (although some states still prohibit sales for recreational purposes). A vast 
quantity of literature exists pertaining to the pros and cons of legalizing marijuana usage via 
analyses conducted in the fields of criminology, sociology, and economics, among others. Several 
studies show that there are marked differences between medical and recreational marijuana strains, 
primary of which being that medical marijuana contains a higher Cannabidiol (CBD) content; 
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whereas the latter, a higher content of Tetrahydrocannabinol (THC) 1 . Is it to be noted that 
investigation has shown that THC content is the factor that seems to provide pain relief. The second 
key distinction is that individuals need to have a qualifying condition in order to obtain a medical 
marijuana recommendation (to be renewed on a regular basis) by a physician; while on the other 
hand, recreational marijuana can be bought by any adult. Given these factors, this paper focuses 





The latest reports by the Centers for Disease Control (CDC) show a substantial proportion 
of the American population overdosing on opioids in recent times; leading to this misuse (of 
opioids) being classified as a national crisis. As opioids are drugs that are generally prescribed for 
chronic pain, their usage, therefore, cannot be entirely stopped. The US Department of Health and 
Human Services (HHS) claims that over a hundred and thirty people a day die from opioid-related 
drug overdoses2. The Colorado Consortium for Prescription Drug Abuse Prevention also estimates 
that opioid overdoses result in three hundred deaths per year in Colorado3. It has been found that 
about twenty-nine percent of patients who were prescribed opioids for chronic pain misuse them 
(Vowles et al., 2015); and that about eighty percent of people who use heroin illegally first misused 
prescription opioids (Muhuri et al., 2013). A recent paper by Alpert et al., (2018) published in the 
American Economic Journal: Economic Policy focuses on the increase in heroin overdoses across 
the U.S. The authors believe that, around 2010, there was a sizeable shift from the abuse of 
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prescription opioids to heroin abuse due to the reformulation of the drug OxyContin which made 
it harder to crush and dissolve. They also observed that the states that saw a large volume of 
existing users switch from the reformulated OxyContin to heroin in the short run, had in fact 
previously recorded high rates of OxyContin misuse. The paper concludes that such supply-side 
disruptions may lead to an increase in substitutes across opioid-drug types rather than reductions 
in overall opioid overdoses. In light of such alarming figures, the National Institutes of Health 
(NIH), in order to help solve the opioid crisis and prevent opioid misuse, has deemed necessary 
the determination of innovative and healthier strategies to manage chronic pain4. While there are 
no marijuana-based products for pain relief approved by the United States Food and Drug 
Administration (FDA) currently, informal evidence exists suggesting that marijuana may in fact 
help ease certain types of chronic pain; thus making it a good focus for this study. 
 
Evaluation 
The analysis in this paper is conducted using the Synthetic Controls Method (SCM), which 
is one of the latest popular methods5 used for evaluating public policy. This is because it delivers 
a quantifiable backing for specific case-studies by generating a “synthetic control region”. This 
hypothetical counterfactual region, generated using statistical software, simulates what the 
outcome path of the state would look like if it had not undergone a particular policy intervention; 
i.e. the trend that the opioid-related death rates would have followed in Colorado if not for 
Amendment 64. This method was carried out by taking the weighted average of pre-legalization 
opioid-related death rates from a list of “control” states. The states forming the synthetic control 
                                               
 
4 https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative 
5 Check: Abadie A. et al. (2010), Billmeier A. & Nannicini T. (2013), Abadie A. & Gardeazabal J. (2003) 
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were selected from the U.S. states that had not legalized marijuana for recreational use during the 
investigative timeline. The affected state (in this case, Colorado) and its synthetic control 
counterpart were then used to study the policy’s effectiveness i.e. how the legalization of marijuana 
for recreational use impacts the opioid-related death rate in the state. 
 
Literature Review 
There is a strong rhetoric for both the positive and the negative sides of the marijuana legalization 
debate. Furthermore, there are a large number of articles that seek to examine the effect of the 
legalization policies and their potential association with opioid use. There is no doubt however, 
that nearly all of the studies agree on the fact that diminishing the dependence on opioids is an 
enormous undertaking, and that this reduction in opioid use must be substituted with alternative 
treatments. The prevailing public opinion in favor of legalizing marijuana, in combination with 
federal guidelines mandating the limited use of opioids could indeed lead to self as well as 
prescribed substitutions of marijuana for opioid use (Choo EK et al., 2016). A study by Hill and 
Saxon published in The Journal of the American Medical Association (JAMA) analyzing more 
than five years of opioid prescription data discovered that post-legalization, the quantity of 
prescriptions decreased substantially; establishing that there was a rampant shift away from opioid 
to marijuana consumption (Hill KP & Saxon AJ, 2018). However, this study could not establish if 
this move was spearheaded by the patients or by the physicians. There appear to be numerous 
studies that center on examining the link between medical marijuana legalization and opioid 
overdose deaths; but fewer that focus on recreational marijuana use due to lack of data and 
opportunity for research. This has led to emerging concerns that while medical marijuana use may 
indeed be a good substitute for prescription opioid use, the use of recreational marijuana may in 
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fact be an accelerant for prescription opioid misuse, making it paramount to understand and look 
into the impact of recreational marijuana laws on opioid consumption levels. The paper by Yuayn 
Shi et al. explores this concern. The authors use state-level quarterly prescription drug utilization 
records for Medicaid enrollees with the aid of difference-in-difference models to conclude that 
there was no evidence that recreational marijuana legalization increased the number of prescription 
opioids; but the policy did reduce the consumption of Schedule III6  opioids in some states 
following the legalization. A related study focusing on recreational marijuana is by Melvin D. 
Livingston et al. (2017). The paper makes use of an interrupted time-series design for the time 
period 2000 to 2015 in order to compare the changes in monthly opioid-related deaths before and 
after the policy. According to the study, after the legalization of marijuana for recreational use in 
Colorado, opioid-related deaths decreased by approximately 0.7 deaths per month. However, there 
have been no studies so far that have employed the SCM to study the effects of this legalization 
policy; and this analysis, precisely, is what this particular paper endeavors to accomplish. 
 
Data & Implementation 
Research Design 
 The investigative timeline was set from 1999 to 2016, on account of available data. This 
period of interest for the study ensured that there were seventeen years of data prior to the 
enactment of the legalization policy. It would have enhanced this study significantly if a larger 
sample of pre-intervention data were available for analysis, thus ensuring a higher degree of 
robustness with respect to the results (Abadie et al., 2010). To begin, the appropriate covariates 
                                               
 
6 Substances that have less potential for abuse than substances classified as Schedules I or II 
  8 
that would possibly have a significant impact on the opioid overdose death rates were identified. 
Given the availability of data, the final list of predictors used were per capita income, 
unemployment rates, the state’s expenditure on health as a percent of GDP, age distribution of the 
population, sex composition of the population, the population’s race make-up, and the educational 
levels of the population. There is scope for the addition of more relevant predictor variables such 
as state crime rates, industry-composition of the state, and so on which could further enrich the 
model. This task, however, was limited due to lack of available data. Next, the donor states that 
would help synthesize the control state were established. The synthetic state is constructed as a 
weighted average of potential control states, chosen such that the resulting synthetic state best 
reproduces the values of the predictors before the legalization of marijuana for recreational use. 
Because the synthetic state is meant to reproduce the opioid overdose death rates that would have 
been observed for the control state (Colorado) in the absence of this legalization policy, the state 
of Washington was excluded from the list of donor due to a similar policy being enacted in the 
considered time frame. 
 
Data Sources & Collection 
Primarily, the comprehensive mortality information contained in the CDC database for 
different opioid classifications was used to collect data on the death rates. CDC data is collected 
on natural opioids (morphine and codeine), semi-synthetic opioids (oxycodone, hydrocodone, 
hydromorphone, and oxymorphone), synthetic opioids (methadone, tramadol, and fentanyl), as 
well as heroin, an illegal opioid synthesized from morphine. Opioid overdose deaths (age-adjusted) 
were acquired from the ‘CDC WONDER’ database using the ‘Mortality Files’7  for the time period 
                                               
 
7 https://wonder.cdc.gov/mcd.html 
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1999 to 2016. Drug overdose deaths were defined according to the 10th revision of the 
International Statistical Classification of Diseases i.e. ICD-10 codes (which included the following 
categories: X40-X44, X60-X64, and Y10-Y14); in addition to specifically opioids (which included 
the following categories: T40.1-T40.4). Data on state unemployment rates and state health 
expenditure for the same time period was collected from the Bureau of Labor Statistics (BLS)8. 
Additionally, data on states-wise demographics such as age, sex, marital status, per capita income, 
and educational level was amassed from the Integrated Public Use Microdata Series (IPUMS)9.  
 
Results 
From Figure 1 below, it can be observed that the trend of opioid-related overdose death rates in 
Colorado and the rest of the United States appear to progress on a similar path.  
And in order to evaluate the effect of the 2012 legalization policy of marijuana for recreational use 
on the aforementioned death rates in Colorado, the fundamental question that arises is: How to 
determine what path these opioid-related death rates would have followed in Colorado in the 












Like discussed above, the synthetic control method provides the best and most systematic way to 
estimate this counterfactual. Synthetic Colorado was constructed as a “convex combination” of the 
states in the donor pool that most closely resembled Colorado in terms of pre-legalization values 
of the relevant predictors. The following table displays the weights of each control state in the 
synthetic Colorado. The weights reported in Table 1 indicate that the opioid-related death trends 
in Colorado prior to the legalization of marijuana for recreational use is best reproduced by a 
combination of the states of Alaska, Arizona, Massachusetts, Nevada, New Hampshire, Utah, and 
Virginia. All the other states present in the donor pool were assigned zero weights. 
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The ensuing results obtained from conducting this analysis are displayed below. Table 2 compares 
the pretreatment opioid-related death rates in addition to other characteristics of the actual state of 
Colorado with that of the generated synthetic Colorado, as well as with the average of the states in 
the donor pool. It can be noted that the SCM does indeed provide a counterfactual that can be 
accurately used for comparison with the treated state, Colorado.  
On the other hand, the average values of the death rates in the states that did not implement the 
legalization policy in the investigative time period of 1999 to 2016 do not seem to provide a 
suitable control group for Colorado when compared to those generated by the formation of the 
synthetic state. Therefore, it can be said with confidence that synthetic Colorado provides a more 
accurate reproduction of the average values of the opioid related death rates that are present in 
actual Colorado. Consequently, the SCM can be used to precisely analyze what path the opioid-
related death trends would have taken in Colorado in the absence of the legalization policy of 2012.  
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Table1: Predictor Means 
Variables Real Colorado Synthetic Colorado Average of Control 
States 
Unemployment Rate 5.3 5.030723 5.6213501 
Percent of Population Aged: 
15 to 24 
25 to 34 
35 to 44 
45 to 54 
55 to 64 


































































Percent of Population that is 
Female 0.5079817 0.5093697 0.615339 
Ln(Per Capita Income) 14.51673 14.53484 14.4823 
Health Expenditure as a 
percentage of GDP 0.1080769 0.1071338 0.1391821 
Lagged Death Rate (2011) 23.3921 22.95417 21.527614 
Lagged Death Rate (2006) 19.3347 19.64065 18.017618 
Lagged Death Rate (2000) 11.7631 11.86461 9.6371611 
 
This table emphasizes an important feature of synthetic control, namely, the ability to safeguard 
against estimation of “extreme counterfactuals that fall far outside the convex hull of the data” 
(King and Zheng 2006). The pre-intervention root mean squared prediction error for Colorado was 
found to be 0.7671137 (which is universally accepted as fairly small); indicating that the SCM is 
able to provide a good fit for the data at hand. 
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Accordingly, Figure 2 displays the trend of opioid-related death rates for Colorado and its synthetic 
counterpart during the time period 1999 to 2016. It can be seen that synthetic Colorado closely 
tracks the path of the opioid-related death rates variable in Colorado for the pre-legalization period 
suggesting that the synthetic Colorado could indeed provide a reasonable approximation to the 
number of opioid-related deaths from 2012 onwards in Colorado in the absence of the legalization 
policy. The two lines begin to diverge noticeably after the legalization went into effect and the real 
Colorado line seem to show a lower rate of increase when compared to the trajectory of the 
synthetic Colorado. The discrepancy between the two lines insinuates a negative effect of the 
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Furthermore, from Figure 3, it can be inferred that the legalization policy did indeed have a large 
negative effect on the number of opioid-related death rates. It can be observed that for the post 
2012 timeframe, i.e., after the recreational legalization policy was enacted, the death rates due to 





In order to evaluate the significance of the estimates, it is important to check the robustness of the 
results obtained and rule out the possibility that the resultant outcomes could be driven entirely by 
chance. Running placebo tests provided one way to answer appropriately the question of chance. 
The placebo test was run by first applying the SCM to the donor states i.e. those states that did not 
enact the policy of legalization of marijuana for recreational use during the sample period i.e. 1999 
to 2012. If the placebo tests showed that the gap estimated for Colorado is large relative to the gaps 
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for the states that did not implement any legalization of recreational marijuana policy, then it could 
be concluded that the analysis provides significant evidence of a negative effect of the 2012 
legalization policy on the deaths due to opioid overdose in the state of Colorado (Abadie et al., 
2010). The series of placebo studies was constructed by iteratively applying the SCM used to 
estimate the effect of the 2012 legalization policy in Colorado to every other state in the donor 
pool. In each iteration, data was reassigned in order to enable investigation as if one of the states 
in the donor pool would have passed the 2012 legalization policy instead of Colorado. The 
estimated effect was then computed with each placebo run providing a distribution of estimated 
gaps for the states where no intervention took place. Figure 4 below displays the results for the 
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The light-colored lines represent the gap associated with each of the donor state runs of the test 
and show the difference in death rates between the respective state and its respective synthetic 
version. As the figure makes apparent, the estimated gap for Colorado after 2012 is large relative 
to the distribution of the gaps for the states in the donor pool.  
 
Discussion 
This report trails the procedure of the SCM described through the paper by Abadie, Diamond, and 
Hainmueller. As their paper acknowledges, “comparative case study research has broad potential 
in the social science but its empirical implementation of is plagued by inferential challenges and 
ambiguity about the choice of valid control groups” (Abadie, A et al., 2010). Hence, using the 
SCM as a data-driven procedure to select the appropriate comparison units provided a suitable 
method to analyze the impact of the legalization of marijuana on deaths due to opioid overuse. 
Using the SCM to analyze the effect of the legalization policy at a county-level analysis rather 
than a state-level analysis may prove to be a more forceful study. This task, however, was outside 
the scope of this study. Nevertheless, this report does strongly indicate that the legalization of 
recreational marijuana would result in a decrease in the number of deaths due to opioid misuse. 
Due to the liberal prescribing of opioid drugs during the 1990s, dependency on and the abuse of 
opioids seems to have grown exponentially in the United States; making the country one of the 
leading consumer of opioids10 (UNODC World Drug Report 2018). Thus, there has been a rise in 
resources and programs being directed toward finding substitutes for chronic-pain treatments that 
could help bring a reprieve to the opioid crisis. Due to emerging research on its medical benefits, 
                                               
 
10 https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf 
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marijuana offers to be a good substitute to look into. It has so far, however, proven difficult to 
study the health impacts of recreational marijuana due to its illegality; causing a hinderance to data 
collection. There has been an ever-increasing public support for marijuana law reform in the recent 
years, as well as encouragement from non-profit organizations such as The Drug Policy Alliance 
(DPA)11 to regulate marijuana similar to alcohol and tobacco. There is general consensus that 
allowing the possession, use and sales of marijuana could in fact increase tax revenue, generate 
commerce and support the agricultural economy. Hence, taking into account all the 
aforementioned factors, it deems a vital mission to understand the health impacts of marijuana. As 
there still exist a lot of unknown aspects regarding how the recreational legalization policy could 
affect marijuana being used as a substitute for opioids, in the treatment of chronic pain, research 
on it, as carried out by this paper, seems to hold pronounced importance in the present-day. 
  
                                               
 
11 http://www.drugpolicy.org/ 
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